


**Global AMR Innovators
Conference
22-24 September 2026
Lisbon, Portugal**

Preliminary Programme



Programme

Tuesday, 22 September 2026

11:00-12:00	Session Hall Integrated symposium: Next steps in enteric antibacterial development: evidence, gaps and actions Organised by GNA NOW
12:00 – 13:00	Welcome coffee ¹ & poster mounting
13:00 – 14:00	Session Hall Welcome and keynote lecture Welcoming address Jon S. Friedland (Chair), UK Aligning R&D with Global AMR Priorities Valeria Gigante, Switzerland The role of artificial intelligence in the development and approval of new antibiotics and antifungals Radu Botgros, Netherlands
14:00 – 14:30	Coffee & pastry break ¹
14:30 – 16:00	Session Hall Diagnostic development. When MICs don't make sense: designing development programmes when standard susceptibility testing breaks down Amy Mathers (Chair), USA Anna Both (Chair), Germany Proving it's not the drug: building the case against standard MIC testing? Jean Patel, USA Designing 'non-standard' testing that reflects <i>in vivo</i> antimicrobial activity? Mariana Castanheira, USA Clinical trials without a standard test: logistics, risk, and reality Srividya Desai, India From approval to adoption: diagnostic constraints and market reality tba
16:00 – 16:30	Session Hall Lightning talks from poster presenters Shampa Das (Chair), UK Taslimarif Saiyed (Chair), India tba
16:30 – 16:45	Break
16:45 – 18:15	Poster area

¹ Included in conference registration

Poster session (drinks served¹)

Category 1: Early Discovery and Development

Category 2: Preclinical Development

Category 3: Clinical Development

Category 4: New antibacterial or antifungal classes

Category 5: Non-traditional approaches

18:15 – 18:30 Break

18:30 – 20:00 Networking area

Opening ceremony & reception (food & drinks served¹)

tba

Programme

Wednesday, 23 September 2026

08:30 – 10:00 Session Hall

Addressing global gaps: accelerating paediatric antibacterial drug development to meet unmet needs

Sumati Nambiar (Chair), USA
Justin Green (Chair), Switzerland

What do we need to do to ensure simultaneous adult and adolescent approvals?
Marcela Ramirez, UK

What can we do to expedite neonatal product development?
Tanu Singhal, India

How do we address the unmet needs of children in LMICs?
Nina Putri, Indonesia

10:00 – 10:30 Coffee & pastry break¹

10:30 – 10:45 Session Hall

CARB-X: A decade in review and a vision for the future

Seamus O'Brian (Chair), UK

CARB-X: A decade in review and a vision for the future
Kevin Outterson, USA

10:45 – 12:00 Session Hall

Challenges and successes in the clinical development of preventatives against AMR

Vega Massignani (Chair), Italy
Richard Alm (Chair), USA

From observational evidence to randomised trials: insights for gonorrhoea vaccine development
Kate Seib, Australia

tba
Veronica Hall, USA

12:00 – 13:00 Lunch break¹

13:00 – 14:00 Session Hall

Decolonisation strategies coming of age: positioning them for success

Erin Duffy (Chair), USA
tba (Chair)
tba

14:00 – 14:30 Coffee & pastry break¹

14:30 - 15:45 Session Hall

From aspiration to application: applying WHO target product profiles to antibiotic R&D

Valeria Gigante (Chair), Switzerland

François Franceschi (Chair), Switzerland

TPP 1: severe MDR Gram-negative infections (BSI, HABP/VABP) caused by CRAB, CRE, CRPA

Anand Kumar, India

TPP 2: meningitis CA and HCA caused by MDR Gram-negative bacteria and methicillin-resistant *S. aureus*

Seun Makinde, USA

Reality check: the European Commission innovation driven rewarding system and the new voucher

Ana Burgos-Guiterrez, Belgium

15:45 – 16:15 Coffee break¹

16:15 – 16:45 Session Hall

Lightning talks from poster presenters

tba

16:45 – 17:30 Session Hall

Keynote lecture

Robert Skov (Chair), Denmark

Beta-lactams in jeopardy – the rise of PBP mutations!

Karen Bush

17:30 – 17:45 Break

17:45 – 19:15 Poster area

Poster session (drinks served¹)

Category 6: Stewardship, Antimicrobial Supply and Access

Category 7: AMR Diagnostics

Category 8: Preventatives / Vaccines

Category 9: AMR Epidemiology

19:30 – 20:30 Networking area

Networking & reception (food & drinks served¹)

Programme

Thursday, 24 September 2026

08:30 – 10:00	Session Hall
	Pragmatic session - narrow-spectrum agents: the challenge of bringing phage therapeutics from concept thru late-stage development
	John Rex (Chair), USA
	Radu Botgros (Chair), Netherlands
	Overview of program design: How phages fit into the antimicrobial armamentarium, how phage differ from traditional products, and why reproducibility is the particular focus of this session
	John Rex, USA
	PK-PD and dose: animal models, combination strategies, dose ratios
	Gauri Rao, USA
	Sustainable manufacturing platform: phage bank development, GMP production, biological variability
	Frenk Smreckar, Slovenia
	A regulatory perspective: the platform approach, timing of regulatory guidance, EMA expectations, role of the magistral formula pathway
	Radu Botgros, Netherlands
10:00 – 10:30	Coffee & pastry break ¹
10:30 – 12:00	Session Hall
	Issues in clinical development
	David Paterson (Chair), Singapore
	Florian Maurer (Chair), Switzerland
	Lessons from a successful superiority trial
	Kevin Mange, USA
	Do we need Phase II clinical trials?
	Clare Nasmyth-Miller, UK
	Single arm trials: is LPAD still an option?
	Sumathi Nambiar, USA
	Panel discussion
	All speakers
12:00 – 13:00	Lunch break ¹
13:00 – 14:00	Session Hall
	Funding for clinical development
	David Paterson (Chair), Singapore
	Richard Alm (Chair), USA
	Sources of non-dilutive funding
	Damiano De Felice, Italy
	AMR Action Fund: who should apply and when?

Henry Skinner, USA

Raising public funds via an IPO

Marc Gitzinger, Switzerland

Is fund-raising for antibiotic trials any easier in a large company?

Kenneth Bradley, Switzerland

14:00 – 14:30 Coffee break¹

14:30 – 15:45 Session Hall

When innovation is not enough: access challenges in antibiotics

Elena Breidenstein (Chair), UK

Regina Osih (Chair), South Africa

Setting the scene on global access to existing and new antibiotics

Yann Ferrisse, Switzerland

Access to existing antibiotics

Jaideep Gogtay, India

Access to reserve antibiotics

Boumediene Soufi, Germany

Panel discussion

All speakers

15:45 – 16:15 Coffee & pastry break¹

16:15 – 17:15 Session Hall

Global insecurity and AMR: adapting narratives to shifting geopolitics

Frédéric Peyrane (Chair), France

Jomana F. Musmar (Chair), USA

AMR conflict progression and One Health implications in policy

Jomana F. Musmar (Chair), USA

Force multipliers of AMR and impact on treatment decisions

Souha Kanj, Lebanon

Investment, development, access, & policies in diverse settings

Manica Balasegaram, Switzerland

National resilience & response impact on federal decisions

Monisha Ashok, USA

17:15 – 17:45 Session Hall

Closing remarks

Jon S. Friedland, UK
